Functional RECAP (REpair CAPacity) assay identifies homologous recombination deficiency undetected by DNA-based BRCAness tests
Meijer, Titia G; Nguyen, Luan; Van Hoeck, Arne; Sieuwerts, Anieta M; Verkaik, Nicole S; Ladan, Marjolijn M; Ruigrok-Ritstier, Kirsten; van Deurzen, Carolien H M; van de Werken, Harmen J G; Lips, Esther H; Linn, Sabine C; Memari, Yasin; Davies, Helen; Nik-Zainal, Serena; Kanaar, Roland; Martens, John W M; Cuppen, Edwin; Jager, Agnes; van Gent, Dik C
(2022) Oncogene, volume 41, issue 26, pp. 3498 - 3506
(Article)
Abstract
Germline BRCA1/2 mutation status is predictive for response to Poly-[ADP-Ribose]-Polymerase (PARP) inhibitors in breast cancer (BC) patients. However, non-germline BRCA1/2 mutated and homologous recombination repair deficient (HRD) tumors are likely also PARP-inhibitor sensitive. Clinical validity and utility of various HRD biomarkers are under investigation. The REpair CAPacity (RECAP) test is
... read more
a functional method to select HRD tumors based on their inability to form RAD51 foci. We investigated whether this functional test defines a similar group of HRD tumors as DNA-based tests. An HRD enriched cohort (n = 71; 52 primary and 19 metastatic BCs) selected based on the RECAP test (26 RECAP-HRD; 37%), was subjected to DNA-based HRD tests (i.e., Classifier of HOmologous Recombination Deficiency (CHORD) and BRCA1/2-like classifier). Whole genome sequencing (WGS) was carried out for 38 primary and 19 metastatic BCs. The RECAP test identified all bi-allelic BRCA deficient samples (n = 15) in this cohort. RECAP status partially correlated with DNA-based HRD test outcomes (70% concordance for both RECAP-CHORD and RECAP-BRCA1/2-like classifier). RECAP selected additional samples unable to form RAD51 foci, suggesting that this functional assay identified deficiencies in other DNA repair genes, which could also result in PARP-inhibitor sensitivity. Direct comparison of these HRD tests in clinical trials will be required to evaluate the optimal predictive test for clinical decision making.
show less
Download/Full Text
Keywords: Antineoplastic Agents/therapeutic use, BRCA1 Protein/genetics, BRCA2 Protein/genetics, Breast Neoplasms/diagnosis, DNA, Female, Homologous Recombination/genetics, Humans, Poly(ADP-ribose) Polymerase Inhibitors/pharmacology, Poly(ADP-ribose) Polymerases/genetics, Recombinational DNA Repair/genetics, Genetics, Molecular Biology, Cancer Research, Journal Article
ISSN: 0950-9232
Publisher: Nature Publishing Group
Note: Funding Information: The authors thank many colleagues from the departments of Molecular Genetics, Medical Oncology and Pathology at Erasmus MC as well as from the Maasstad hospital, who contributed to the collection of patient material. We thank Dorine den Toom for her assistance with the DNA isolations. This publication has been made possible partly by the data that the Hartwig Medical Foundation and CPCT have made available to the study (data request no. DR-026). Funding Information: DCvG, AJ, and RK have received funding from the Dutch Cancer Society (Alpe d’Huzes grant number EMCR 2014-7048 and grant number EMCR 2008-4045). This work is part of the Oncode Institute which is partly financed by the Dutch Cancer Society and was funded by the gravitation program CancerGenomiCs.nl from the Netherlands Organization for Scientific Research (NWO). Publisher Copyright: © 2022, The Author(s).
(Peer reviewed)